Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Results from the global SENTRY Antimicrobial Surveillance Program (2008)

Journal of Clinical Microbiology

Volumn 48, Issue 8, 2010, Pages 2984-2987

  Messer, Shawn A ^a   Jones, Ronald N ^a,b   Moet, Gary J ^a   Kirby, Jeffrey T ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN; FUNGAL PROTEIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; COMPARATIVE STUDY; CRYPTOCOCCUS; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; FKS FUNGAL GENE; FKS1 FUNGAL GENE; FUNGAL GENE; FUNGUS ISOLATION; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA GLABRATA;

EID: 77955458803     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00328-10     Document Type: Article

References (19)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. (Pubitemid 127774267)
2. Arendrup, M. C., G. Garcia-Effron, C. Lass-Florl, A. G. Lopez, J. L. Rodriguez-Tudela, M. Cuenca-Estrella, and D. S. Perlin. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob. Agents Chemother. 54:426-439.
3. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
4. Castanheira, M., L. N. Woosley, D. J. Diekema, S. A. Messer, R. N. Jones, and M. A. Pfaller. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
5. CLSI. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI. 2008. M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Desnos-Ollivier, M., S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, and E. Dannaoui. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
9. Espinel-Ingroff, A., A. Fothergill, M. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, M. A. Pfaller, M. G. Rinaldi, W. Schell, and T. J. Walsh. 2007. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J. Clin. Microbiol. 45:2180-2182.
10. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
11. Hajjeh, R. A., M. E. Brandt, and R. W. Pinner. 1995. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol. Rev. 17:303-320.
12. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., vol. 2. ASM Press, Washington, DC.
13. Hsueh, P. R., J. R. Graybill, E. G. Playford, S. P. Watcharananan, M. D. Oh, K. Ja'alam, S. Huang, V. Nangia, A. Kurup, and A. A. Padiglione. 2009. Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific region. Int. J. Antimicrob. Agents 34:205-209.
14. Messer, S. A., J. T. Kirby, H. S. Sader, T. R. Fritsche, and R. N. Jones. 2004. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54:1051-1056.
15. Messer, S. A., G. J. Moet, J. T. Kirby, and R. N. Jones. 2009. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47:1942-1946.
16. Odabasi, Z., V. L. Paetznick, J. R. Rodriguez, E. Chen, and L. Ostrosky-Zeichner. 2004. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48:1912-1915.
17. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
18. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068.
19. Verweij, P. E., and M. E. Brandt. 2007. Asperigillus, Fusarium, and other opportunistic moniliaceous fungi, p. 1802-1838. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., vol. 2. ASM Press, Washington, DC.